BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids - 27 Fun Plans to Make Film Evenings Seriously Energizing (You'll Cherish #5!)
- 3Simple Consideration Plants for Home and Office: An Aide
- 4Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- 5Make your choice for the bird that catches your heart!
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Favored Vehicle for Seniors: Make Your Determination
- 7 Moves toward a Sound and Dynamic Way of life
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- Viable Correspondence: Building Solid Connections
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- Vacation spots in America
- Language Learning Applications for Voyagers
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
